Incident Sexually Transmitted Infection as a Biomarker for High-Risk Sexual Behavior After Diagnosis of Acute HIV by Cope, Anna B. et al.
Incident sexually transmitted infection as a biomarker for high
risk sexual behavior following diagnosis with acute HIV
Anna B. Cope, MPH1, Amanda M. Crooks, BS2, Tammy Chin, BS3, JoAnn D. Kuruc, MSN,
RN2, Kara S. McGee, MSPH, PA-C3, Joseph J. Eron, MD2, Charles B. Hicks, MD3, Lisa B.
Hightow-Weidman, MD, MPH2, and Cynthia L. Gay, MD, MPH2
1Department of Epidemiology, University of North Carolina, Chapel Hill, NC
2School of Medicine, University of North Carolina, Chapel Hill, NC
3School of Medicine, Duke University, Durham, NC
Abstract
Background—Sexually transmitted infection (STI) diagnosis following diagnosis of acute HIV
infection (AHI) indicates ongoing high-risk sexual behavior and possible risk of HIV
transmission. We assessed predictors of STI acquisition and the effect of time since care entry on
STI incidence in AHI patients in care and receiving consistent risk-reduction messaging.
Methods—Data on incident gonorrhea, chlamydia, trichomoniasis, primary/secondary syphilis,
demographic, and clinical risk factors were abstracted from medical charts for patients diagnosed
with AHI and engaged in care. Poisson regression models using generalized estimating equations
were fit to estimate incidence rates (IR), incidence rate ratios (IRR), and robust 95% confidence
intervals (CI).
Results—Among 185 AHI patients, 26 (14%) were diagnosed with ≥1 incident STI over 709.4
person-years; 46 STIs were diagnosed during follow-up (IR=6.8/100 person-years). The median
time from HIV care entry to first STI diagnosis was 609 days (range=168–1681). Men who have
sex with men (MSM) (p=0.03), a shorter time between presentation to medical care and AHI
diagnosis (p=0.06), and STI diagnosis prior to AHI diagnosis (p=0.0003) were predictors of
incident STI. STI IR >1 year after entering care was double that of patients in care ≤1 year
(IRR=2.0 95% CI 0.8–4.9). HIV viral load was above the limits of detection within 1 month of 11
STI diagnoses in 6 patients (23.1%) (median=15,898 copies/mL, range=244–152,000 copies/mL).
Conclusions—Despite regular HIV care, STI incidence was high among this primarily young,
MSM AHI cohort. Early antiretroviral initiation may decrease HIV transmission given ongoing
risk behaviors despite risk-reduction messaging.
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Acute HIV infection (AHI) contributes disproportionately to HIV transmission,1–4 with
elevated levels of HIV virus in blood and semen during AHI providing a plausible biological
mechanism for efficient sexual transmission of disease.5,6 Elevated co-infection rates with
sexually transmitted infections (STIs),7,8 increased numbers of partnerships,9,10 and ongoing
high risk sexual behavior4,11,12 during AHI facilitate increase disease transmission. Prompt
linkage and engagement in HIV clinical care, particularly following diagnosis of AHI, is
paramount to reducing HIV transmission. Awareness of HIV diagnosis can alter behavior,
whereby individuals limit their sexual encounters to partners whom they believe to be HIV-
positive (serosorting) and decrease the number of sexual partners.11,13 Furthermore,
initiation of effective antiretroviral therapy (ART) following linkage and engagement in care
during AHI can reduce transmission given evidence of rapid viral suppression.14 However,
some persons diagnosed with AHI maintain high risk sexual behaviors after diagnosis,
including failure to use condoms.11,12 Accordingly, secondary prevention interventions
during AHI remain critical given the increased infectiousness during this period and the
temporal relation to behaviors leading to HIV acquisition.
By definition, individuals diagnosed with AHI become aware of their status very early
following acquisition. The high risk of transmission during AHI and the inherent proximity
to risk factors leading to HIV acquisition warrant evaluation of sexual behavior during and
following diagnosis. An incident STI following HIV diagnosis can be used as a biomarker of
high risk sexual behavior and possible risk of HIV transmission.7,15 In this study, we
estimated STI incidence rates among a cohort of individuals diagnosed with AHI and
receiving care between 1998 and 2012 in two clinics located in the Southeastern United
States, to assess ongoing high risk sexual behavior. We also assessed predictors of STI
acquisition while receiving care and the effect of time since entry into care on STI
incidence.
Materials and Methods
Study Population and Design
We performed a retrospective cohort evaluation of STI incidence among all persons
diagnosed with AHI between January 1, 1998 and March 1, 2012 linking to care at the
University of North Carolina (UNC) or Duke University, and enrolling in an open-label
treatment study within 30 days of AHI diagnosis and/or an AHI observational study as
previously described.14,16 AHI was defined as a negative or indeterminate enzyme
immunoassay or a negative HIV RNA test within 45 days of study enrollment plus
reproducibly detectable HIV RNA by amplification methods. Patients enrolled in the
observational cohort study typically maintain contact with HIV care providers at UNC or
Duke University at least once every six months. During study visits, patients receive
consistent prevention messaging, including targeted discussions with their provider and
trained study coordinators about condom use, sexual and needle-sharing partners, and drug
and alcohol use. Only patients with at least 12 weeks of follow-up through June 30, 2012
were included in this analysis.
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Data Collection: Patient Information
Basic demographic and clinical information was collected on all persons enrolled in study,
including age at diagnosis, gender, race (African-American [AA], other race), sexual risk
group (female, heterosexual male, or men who have sex with men [MSM]), receipt of ART
within 45 days of enrollment, CD4 cell count at enrollment, and viral load (VL) at
enrollment. History of STI diagnosis prior to AHI diagnosis, including, Neisseria
gonorrhoeae (GC), Chlamydia trachomatis (CT), Trichomonas vaginalis (TV), primary,
secondary, or early latent syphilis, Condyloma (warts), herpes simplex virus, Hepatitis B,
Pelvic Inflammatory Disease, and Nongonococcal Urethritis, was recorded. We also
collected information on the time from first presentation to a health care facility with AHI-
related illness to AHI diagnosis and the calendar year of AHI diagnosis.
Data Collection: STI Testing
STI testing and diagnosis dates for GC, CT, TV, and primary/secondary syphilis after
enrolling in care were abstracted from medical and study charts for patients included in this
analysis at UNC and Duke University. Diagnoses were based on clinical and laboratory data
obtained as a part of routine HIV clinical care. Enrollment in the open-label treatment study
included screening for GC, CT and syphilis. However, STI testing during follow-up was not
part of study protocol for the treatment or observational studies. Screening varied among
providers and was done as part of clinical care. Per study protocols, patients were also asked
at each visit about intervening care and treatment, including STI screening, by outside
providers. Verified STI testing results from these outside facilities were routinely requested
and included in this analysis.
To limit the misclassification of prevalent STIs at the time of AHI diagnosis as incident
STIs, we restricted STI testing to at least 28 days after study enrollment. An incident GC or
CT diagnosis was defined as a positive cervical, urethral, rectal or urine test by culture or
nucleic acid amplification. For TV, incident diagnoses included those with a clinical
diagnosis supplemented by a positive wet mount or the presence of T. vaginalis on
Papanicolaou smear or urine PCR. Incident primary/secondary syphilis were identified by a
reactive non-treponemal test (RPR) confirmed by a treponemal test (MHA-TP). A clinician
reviewed all data to confirm incident STI diagnosis. We included positive STI tests for
which incidence could be verified (positive tests with a record of a prior negative test at or
after AHI diagnosis or presence of STI-related symptoms at the time of the positive test).
For syphilis only, positive tests in which the stage of disease could not be determined from
RPR and/or MHA-TP results were excluded.
Statistical Analyses
We used χ2 and Wilcoxon rank-sum tests to compare demographic and clinical
characteristics of patients with at least 1 incident STI to those who did not acquire a STI
during follow-up. Patients were followed from date of enrollment on the treatment or
observational study to the first of the following: administrative censoring at the last date of
STI ascertainment (June 30, 2012) or loss to follow-up (defined as 8 months without a clinic
or study visit from the last date of any clinical activity). Because a person could have more
than 1 STI, Poisson regression models, using generalized estimating equations and an
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exchangeable correlation matrix, were fit to estimate incidence rates (IR), incidence rate
ratios (IRR), and robust 95% confidence intervals (CI) for all STIs and by age, race, gender,
sexual risk group, calendar year of diagnosis, and history of a STI diagnosis prior to AHI
diagnosis. We repeated this analysis to assess differences in screening rates.
We also estimated the effect of time since entering care on STI incidence. Time since HIV
care entry was categorized as ≤1, 2, 3, 4, and ≥5 years, based on minimizing heterogeneity
within categories, preserving power to provide robust estimates, and allowing a longitudinal
representation. Based on a review of the literature and a construction of a directed acyclic
graph, we adjusted our model for sexual risk group and a history of STI diagnosis prior to
AHI diagnosis. All statistical analyses were conducted in SAS version 9.3 (Cary, NC). The
study was approved by the UNC and Duke University Institutional Review Boards. All
participants provided written informed consent.
Results
Between January 1, 1998 and March 1, 2012, 185 AHI diagnoses enrolled in a treatment or
longitudinal study at UNC or Duke University. The majority of participants were AA (57%,
N=106) and male (88%, N=162). Among the men, 82% (N=135) self-identified as MSM.
The median age at diagnosis was 26 years (IQR 22–36). At enrollment, the median baseline
CD4 cell count was 489 cells/mm3 (IQR 343–674) and the median VL was 457,895
copies/mL (IQR 78,115–2,030,000). Patients were followed for a median of 3.3 years (IQR
1.8–5.5) and contributed 709.4 person-years of observation.
A total of 591 laboratory tests for STIs in 113 patients were performed during follow-up,
(116 GC, 116 CT, 3 TV, and 356 primary/secondary syphilis tests). The median time to the
first STI test was 216 days (IQR 112–520). Seventy-two (39%) patients had no recorded
history of STI testing during follow-up. Statistically significant differential screening rates
were observed among patients with a history of a STI diagnosis (IRR=2.3, 95% CI 1.5–3.6),
≤25 years (IRR=0.4, 95% CI 0.3–0.7), and who self-identified as MSM (IRR=2.0, 95% CI
1.1–3.5).
Twenty-six (14%) patients were diagnosed with at least 1 STI during follow-up and 9 (35%)
of who were diagnosed with >1 STI (range 2–7). Nearly 80% of patients diagnosed with an
incident STI had previously been diagnosed with a STI and one-third had a bacterial STI
diagnosis in the 8 weeks preceding their AHI diagnosis. Patients diagnosed with at least 1
STI were more likely to be MSM, experience a shorter time period between first
presentation to a healthcare facility and AHI diagnosis, and have a history of STI diagnoses
than patients without an incident STI (Table 1). A total of 3 incident STIs were diagnosed in
2 individuals who did not identify as MSM. Patients diagnosed with an incident STI were
followed longer than those not diagnosed with an incident STI (Table 1). When considering
only patients with a record of STI testing, the follow-up time for patients without an incident
STI diagnosis increased (median 3.5 years (IQR 2.4–5.8)) and the difference between groups
became statistically non-significant (p=0.3). The median time to first incident STI was 609
days (range 168–1681) after enrollment.
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During follow-up, 46 STIs were diagnosed, including 21 cases of primary/secondary
syphilis, 15 GC, 9 CT, and 1 TV. Five additional positive STI results were excluded because
timing of STI acquisition could not be determined (3 syphilis and 2 GC diagnoses). This
resulted in an overall incidence rate of 6.8 diagnoses/100 person-years (95% CI 4.2–11.0)
(Table 2). The highest STI-specific incidence rate was identified for syphilis (2.9
diagnoses/100 person-years).
STI IRs varied by demographic and clinical categories (Table 3). Patients with a history of
STI diagnoses were more likely to be diagnosed with an incident STI during follow-up than
those with no history (IRR 3.0 95% CI 1.0–9.6). IRs were also highest among AA (IRR 1.9,
95% CI 0.7–5.6), while rates were lower among older (>25 years) patients (IRR 0.2 95% CI
0.1–0.6). IRs increased monotonically by calendar year of AHI diagnosis, ranging from 1.7
(95% CI 0.2–11.6) if diagnosed between 1998–2002 to 10.4 (95% CI 4.6–23.3) if diagnosed
between 2009–2012, despite constant STI testing across diagnosis-year cohorts. During
follow-up, the proportion of all AHI infections that were among persons aged ≤25 years
increased from approximately 45% in 1998–2002 to 62% in 2009–2012 (p=0.05). The STI
IR within this younger population was larger than that in the cohort as a whole at every time
point, except 2003–2005 (Table 3).
STI IRs increased as the time following entry into care increased. For all STIs combined, the
crude IR increased through 3 years after enrollment, at which point rates began declining
(Figure 1A). This same trend was observed in point estimates in multivariable analysis
controlling for history of STI diagnosis and sexual risk group, although the point estimates
were attenuated (Figure 1B). When the time since entering care was dichotomized at 1 year
after AHI diagnosis, the STI IR >1 year after entering care was double that of patients in
care ≤1 year (IRR=2.0 95% CI 0.8–4.9) (Table 3). This comparison in both the unadjusted
rates (p=0.1) and the rates adjusted for history of STI diagnosis and sexual risk group
(p=0.1) were not statistically significant.
The most proximate VL to the date of incident STI diagnosis was above detectable limits
(>50 copies/mL) at the time of 11 STI diagnoses in 6 patients (median=2 STIs/person; range
1–4 STIs/person). All detectable VLs were within 1 month of STI diagnoses. The median
detectable VL at the time of incident STI diagnosis was 15,898 copies/mL (range 244–
152,000). A total of 7 (64%) STIs diagnosed with a detectable VL occurred while the patient
was not on ART. In 4 of 7 STI diagnoses in patients not on ART, an increase in VL was
observed at the time of the STI diagnoses from the previous VL. The median detectable VL
was lower for STIs diagnosed in patients on ART compared to patients not on ART (393
versus 2,297 copies/mL) (Figure 2). For patients on ART at the time of incident STI
diagnosis, the median time from ART initiation to STI diagnosis was 278 days (range 208 to
939).
Discussion
Our results suggest that despite regular assessment and counseling on risk behaviors during
routine study and care visits, STI incidence was high, at a rate of 6.8 diagnoses/100 person-
years, among this primarily young, MSM cohort diagnosed with AHI. Only 7 of 46 STIs
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were diagnosed in the first year after AHI diagnosis. The median time to the first STI
diagnosis in this population was over 1 year, which suggests a change in sexual behavior in
the period immediately following AHI diagnosis. STI incidence >1 year after entering care
was approximately double that of patients who had been in care for ≤1 year. The results
suggest IRs increased yearly after entering care, peaking at approximately 3 years. However,
CIs were wide and overlapped at each time period. The decrease in STI IRs observed in this
cohort ≥4 years after enrollment is at least partially due to fewer patients being followed for
longer time points.
Previous studies have shown similar risk behavior modifications upon notification of HIV
diagnosis, including a decline in unprotected anal intercourse, an increase in serosorting
practices, and a reduction in the number of partners.10–12,17 Persons newly-diagnosed with
AHI often experience illnesses related to seroconversion and/or a period of psychological
adjustment to their diagnosis. This phase is temporary, and presumably any behavior
modifications associated with becoming aware of one’s HIV diagnosis could attenuate over
time.11
As evidenced by high rates of STI diagnoses prior to AHI diagnosis, patients in this cohort
appear to return to risk behaviors they engaged in prior to their AHI diagnosis, despite
consistent, directed risk-reduction messaging during HIV care visits. Interventions to
maintain longer-term behavior change and prevent onward HIV transmission are needed in
persons with a history of STI diagnoses, and may need to focus on different contextual and
situational factors that influence young MSM, such as increased use of the internet to meet
partners and high rates of STIs in sexual networks.18–20
Approximately one-quarter of patients diagnosed with a STI during follow-up were viremic
within 1 month of STI diagnosis. Viremia was expectedly higher among those not on ART
as compared to those on treatment. Given that STIs have been found to increase HIV
concentrations in genital lesions and semen, thereby amplifying the potential of
transmission,21 it is important to ensure all HIV-infected patients, regardless of CD4 cell
count, are treated with ART in a timely manner.22 ART during AHI can rapidly suppress
viremia and protect sexual partners from becoming infected with HIV despite on-going high
risk sexual behavior.
This study has several limitations. First, both the sample size and the number of patients
with a STI during follow-up were relatively small, limiting our power to assess the
association of time since AHI diagnosis and incident STI. Second, the study may not be
generalizable beyond the Southeastern United States. Third, this study was conducted as a
retrospective, secondary analysis of an observational and open-label treatment study whose
primary aims did not include the assessment of incident STI diagnoses. STI screening at
follow-up visits was not standardized, but rather ordered as clinically determined by
individual HIV providers. Further, differential screening rates among young MSM with a
history of STI diagnoses may have contributed to higher STI IRs observed in this sub-
population. Because patients can screen and be diagnosed with STIs at locations other than
Duke University and UNC Infectious Disease Clinics, we could not achieve complete case
ascertainment. Despite our efforts to include all lab verified STI testing and diagnoses
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performed at outside sites, it is likely that the estimates provided underestimate the true IR
in this population. A similar assessment performed on the entire HIV patient population
(both acutely- and chronically-infected patients) receiving care at UNC estimated the STI
incidence as 2.7 cases/100 person-years (95% CI 2.3–3.1) (unpublished data). This was
markedly lower than the likely underestimated IRs provided in this analysis, suggesting STIs
cause considerable morbidity in persons diagnosed during AHI. As recommended by the
Centers for Disease Control,23 regular screening of STIs among patients diagnosed during
AHI and in care is important, as this population continues to engage in risk behaviors at a
higher rate than persons diagnosed at later stages of disease.
Finally, this study is limited by the lack of data on the HIV status of the partners of AHI
patients, preventing any conclusions about onward transmission of HIV. It is possible that
some patients were practicing serosorting behaviors and acquired STIs from HIV-positive
partners. The majority of STI diagnoses occurred in patients on treatment with undetectable
VLs. Previous research indicates an association between a person’s belief that an
undetectable VL reduces infectiousness and engaging in unprotected anal intercourse,
regardless of the partner’s HIV status.24 This phenomenon could reduce transmission of
HIV, but fail to protect against the transmission of other STIs. Additional messaging is
needed during HIV care visits to inform patients about continued risk of STI acquisition
with serosorting and unprotected sex while undetectable, despite reductions in HIV
transmission risk.
Our results suggest a persistence of high risk sexual behavior in this young, primarily MSM
cohort, despite receipt of regular prevention messages at study and HIV care visits.
Healthcare providers should take advantage of each care encounter to address STI
assessment, risk-reduction messaging, and HIV management. We believe annual STI
screenings for syphilis, GC and CT (at a minimum) are critical to monitor STI acquisition
and risk behavior present in this patient population.25 Approximately 92% of the AHI
patients diagnosed with a STI during follow-up were MSM, suggesting tailored risk
prevention interventions are needed to address ongoing risk behaviors in this group.26,27
Finally, these data strongly support the importance of ART initiation in those diagnosed
with AHI, as specifically recommended in revised guidelines,22 to reduce the risk of onward
HIV transmission in the presence of continued high risk sexual behavior.
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Incidence rates (IR) and robust 95% confidence intervals (CI) by time since entry into care.
Figure 1A shows unadjusted IR and robust 95% CI over the study period. Figure 1B shows
the IR and robust 95% CI adjusted for sexual risk group and history of a STI diagnosis.
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Viral load (VL) values of patients with detectable HIV RNA (>50 copies/mL) at the time of
STI diagnosis by antiretroviral treatment status.
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Table 2





All Incident STIs 46 6.8 (4.2–11.0)
By Disease
Chlamydia 9 1.3 (0.6–2.8)
Syphilis 21 2.9 (1.8–4.8)
Gonorrhea 15 2.2 (1.0–4.7)
Trichomonias 1 0.1 (0.0–0.9)
*
Rates and robust 95% CI were calculated using an exchangeable correlation matrix. Rates are based on 709.2 person-years of follow-up and are
presented per 100 person-years
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